社区起始氯氮平治疗的真实世界临床与成本效益:镜像队列研究
该自然主义镜像队列研究纳入158例被推荐接受氯氮平治疗的社区患者,其中88例(56%)同意起始氯氮平,58例(66%)成功建立治疗。社区起始成功率为65.4%,与住院起始的58.82%无显著差异(χ2(1,88)=0.47,P=0.49)。起始氯氮平后,1年和2年门诊访视次数中位数显著减少,精神科住院床日减少74.71%,服务使用成本显著降低,症状严重程度在出院时和2年随访时均显著改善。
要点
- 社区起始氯氮平成功率为65.4%,与住院起始的58.82%无显著差异(P=0.49)。
- 起始氯氮平后1年和2年门诊访视中位数显著减少,精神科住院床日减少74.71%。
- 服务使用成本1年降低963英镑/患者,2年降低1598.10英镑/患者,均P<0.001。
核心结论
- 社区起始氯氮平可行,且与成本、服务使用和症状严重程度的显著降低相关。
研究设计与样本
- 自然主义镜像队列研究,纳入158例被推荐接受氯氮平治疗的社区患者。
主要发现
- 158例被推荐接受氯氮平治疗的患者中,88例(56%)同意起始氯氮平,其中58例(66%)成功建立治疗。
- 社区起始成功率为65.4%,住院起始成功率为58.82%,两者无显著差异(χ2(1,88)=0.47,P=0.49)。
- 起始氯氮平后1年门诊访视中位数从24.00次(四分位距IQR=14.00-41.00)降至13.00次(IQR=5.00-24.00),P<0.001;2年从47.50次(IQR=24.75-71.00)降至22.00次(IQR=11.00-42.00),P<0.001。
- 精神科住院床日减少74.71%(z=-2.50,P=0.01)。
- 服务使用成本1年降低963英镑/患者(P<0.001),2年降低1598.10英镑/患者(P<0.001);仅社区起始亚组分析1年降低827.40英镑/患者(P<0.001),2年降低1668.50英镑/患者(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is the only drug licensed for treatment-resistant schizophrenia (TRS) but the real-world clinical and cost-effectiveness of community initiation of clozapine is unclear. AIMS: The aim was to assess the feasibility and cost-effectiveness of community initiation of clozapine. METHOD: This was a naturalistic study of community patients recommended for clozapine treatment. RESULTS: Of 158 patients recommended for clozapine treatment, 88 (56%) patients agreed to clozapine initiation and, of these, 58 (66%) were successfully established on clozapine. The success rate for community initiation was 65.4%; which was not significantly different from that for in-patient initiation (58.82%, χ2(1,88) = 0.47, P = 0.49). Following clozapine initiation, there was a significant reduction in median out-patient visits over 1 year (from 24.00 (interquartile range (IQR) = 14.00-41.00) to 13.00 visits (IQR = 5.00-24.00), P < 0.001), and 2 years (from 47.50 visits (IQR = 24.75-71.00) to 22.00 (IQR = 11.00-42.00), P < 0.001), and a 74.71% decrease in psychiatric hospital bed days (z = -2.50, P = 0.01). Service-use costs decreased (1 year: -£963/patient (P < 0.001); 2 years: -£1598.10/patient (P < 0.001). Subanalyses for community-only initiation also showed significant cost reductions (1 year: -£827.40/patient (P < 0.001); 2 year: -£1668.50/patient (P < 0.001) relative to costs prior to starting clozapine. Relative to before initiation, symptom severity was improved in patients taking clozapine at discharge (median Positive and Negative Syndrome Scale total score: initial visit: 80 (IQR = 71.00-104.00); discharge visit 50.5 (IQR = 44.75-75.00), P < 0.001) and at 2 year follow-up (Health of Nation Outcome Scales total score median initial visit: 13.00 (IQR = 9.00-15.00); 2 year follow-up: 8.00 (IQR = 3.00-13.00), P = 0.023). CONCLUSIONS: These findings indicate that community initiation of clozapine is feasible and is associated with significant reductions in costs, service use and symptom severity.
引用
- Butler E, Pillinger T, Brown K, et al. Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. Br J Psychiatry. 2022. PMID: 35438068. doi:10.1192/bjp.2022.47
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。